New approaches and potential treatments for dry age-related macular degeneration

Detalhes bibliográficos
Autor(a) principal: Damico,Francisco Max
Data de Publicação: 2012
Outros Autores: Gasparin,Fabio, Scolari,Mariana Ramos, Pedral,Lycia Sampaio, Takahashi,Beatriz Sayuri
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos brasileiros de oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492012000100016
Resumo: Emerging treatments for dry age-related macular degeneration (AMD) and geographi c atrophy focus on two strategies that target components involved in physiopathological pathways: prevention of photoreceptors and retinal pigment epithelium loss (neuroprotection induction, oxidative damage prevention, and visual cycle modification) and suppression of inflammation. Neuroprotective drugs, such as ciliary neurotrophic factor, brimonidine tartrate, tandospirone, and anti-amyloid β antibodies, aim to prevent apoptosis of retinal cells. Oxidative stress and depletion of essential micronutrients are targeted by the Age-Related Eye Disease Study (AREDS) formulation. Visual cycle modulators reduce the activity of the photoreceptors and retinal accumulation of toxic fluorophores and lipofuscin. Eyes with dry age-related macular degeneration present chronic inflammation and potential treatments include corticosteroid and complement inhibition. We review the current concepts and rationale of dry age-related macular degeneration treatment that will most likely include a combination of drugs targeting different pathways involved in the development and progression of age-related macular degeneration.
id CBO-2_c02ef514c3db7cc9b265d8e018163279
oai_identifier_str oai:scielo:S0004-27492012000100016
network_acronym_str CBO-2
network_name_str Arquivos brasileiros de oftalmologia (Online)
repository_id_str
spelling New approaches and potential treatments for dry age-related macular degenerationMacular degeneration/drug therapyRetinaRetinal pigment epitheliumInflammationComplement activationEmerging treatments for dry age-related macular degeneration (AMD) and geographi c atrophy focus on two strategies that target components involved in physiopathological pathways: prevention of photoreceptors and retinal pigment epithelium loss (neuroprotection induction, oxidative damage prevention, and visual cycle modification) and suppression of inflammation. Neuroprotective drugs, such as ciliary neurotrophic factor, brimonidine tartrate, tandospirone, and anti-amyloid β antibodies, aim to prevent apoptosis of retinal cells. Oxidative stress and depletion of essential micronutrients are targeted by the Age-Related Eye Disease Study (AREDS) formulation. Visual cycle modulators reduce the activity of the photoreceptors and retinal accumulation of toxic fluorophores and lipofuscin. Eyes with dry age-related macular degeneration present chronic inflammation and potential treatments include corticosteroid and complement inhibition. We review the current concepts and rationale of dry age-related macular degeneration treatment that will most likely include a combination of drugs targeting different pathways involved in the development and progression of age-related macular degeneration.Conselho Brasileiro de Oftalmologia2012-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492012000100016Arquivos Brasileiros de Oftalmologia v.75 n.1 2012reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.1590/S0004-27492012000100016info:eu-repo/semantics/openAccessDamico,Francisco MaxGasparin,FabioScolari,Mariana RamosPedral,Lycia SampaioTakahashi,Beatriz Sayurieng2012-04-27T00:00:00Zoai:scielo:S0004-27492012000100016Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2012-04-27T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false
dc.title.none.fl_str_mv New approaches and potential treatments for dry age-related macular degeneration
title New approaches and potential treatments for dry age-related macular degeneration
spellingShingle New approaches and potential treatments for dry age-related macular degeneration
Damico,Francisco Max
Macular degeneration/drug therapy
Retina
Retinal pigment epithelium
Inflammation
Complement activation
title_short New approaches and potential treatments for dry age-related macular degeneration
title_full New approaches and potential treatments for dry age-related macular degeneration
title_fullStr New approaches and potential treatments for dry age-related macular degeneration
title_full_unstemmed New approaches and potential treatments for dry age-related macular degeneration
title_sort New approaches and potential treatments for dry age-related macular degeneration
author Damico,Francisco Max
author_facet Damico,Francisco Max
Gasparin,Fabio
Scolari,Mariana Ramos
Pedral,Lycia Sampaio
Takahashi,Beatriz Sayuri
author_role author
author2 Gasparin,Fabio
Scolari,Mariana Ramos
Pedral,Lycia Sampaio
Takahashi,Beatriz Sayuri
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Damico,Francisco Max
Gasparin,Fabio
Scolari,Mariana Ramos
Pedral,Lycia Sampaio
Takahashi,Beatriz Sayuri
dc.subject.por.fl_str_mv Macular degeneration/drug therapy
Retina
Retinal pigment epithelium
Inflammation
Complement activation
topic Macular degeneration/drug therapy
Retina
Retinal pigment epithelium
Inflammation
Complement activation
description Emerging treatments for dry age-related macular degeneration (AMD) and geographi c atrophy focus on two strategies that target components involved in physiopathological pathways: prevention of photoreceptors and retinal pigment epithelium loss (neuroprotection induction, oxidative damage prevention, and visual cycle modification) and suppression of inflammation. Neuroprotective drugs, such as ciliary neurotrophic factor, brimonidine tartrate, tandospirone, and anti-amyloid β antibodies, aim to prevent apoptosis of retinal cells. Oxidative stress and depletion of essential micronutrients are targeted by the Age-Related Eye Disease Study (AREDS) formulation. Visual cycle modulators reduce the activity of the photoreceptors and retinal accumulation of toxic fluorophores and lipofuscin. Eyes with dry age-related macular degeneration present chronic inflammation and potential treatments include corticosteroid and complement inhibition. We review the current concepts and rationale of dry age-related macular degeneration treatment that will most likely include a combination of drugs targeting different pathways involved in the development and progression of age-related macular degeneration.
publishDate 2012
dc.date.none.fl_str_mv 2012-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492012000100016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492012000100016
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-27492012000100016
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Oftalmologia v.75 n.1 2012
reponame:Arquivos brasileiros de oftalmologia (Online)
instname:Conselho Brasileiro de Oftalmologia (CBO)
instacron:CBO
instname_str Conselho Brasileiro de Oftalmologia (CBO)
instacron_str CBO
institution CBO
reponame_str Arquivos brasileiros de oftalmologia (Online)
collection Arquivos brasileiros de oftalmologia (Online)
repository.name.fl_str_mv Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)
repository.mail.fl_str_mv aboonline@cbo.com.br||abo@cbo.com.br
_version_ 1754209027233939456

Registros relacionados